Emerging Innovations in Psychedelic Healthcare
Psychedelic medicines are entering the latter stages of drug development, progressing from Phase II to Phase III trials, with the sector anticipating their approval and arranging for their adoption.
For drug developers this means focussing on commercialisation strategies, identifying the treatment’s expected patient journey and market size, and collaborating with regulators, healthcare providers and payees to maximise treatment accessibility.
They will also need to mitigate potential bottlenecks and create services that promote the therapy’s integration into existing healthcare frameworks.
As the industry approaches significant milestones in the adoption of psychedelic healthcare, PSYCH spoke with decision makers from across the ecosystem.READ MORE